Compare Agilysys Inc (AGYS) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilysys Inc vs Becton Dickinson and Co — how do they compare? Agilysys Inc trades at $106.65 (market cap $3.18B), while Becton Dickinson and Co trades at $151.68 (market cap $43.07B). The key difference: Becton Dickinson and Co is far larger — about 13.5× Agilysys Inc's market cap, and Becton Dickinson and Co pays a 2.69% dividend while Agilysys Inc pays none. Which is the better fit depends on your goals.
| AGYS | BDX | |
|---|---|---|
Market Cap | $3.18B | $43.07B |
Sector | Technology | Health |
52-Week High | $141.12 | $185.39 |
52-Week Low | $62.19 | $135.49 |
Enterprise Value | $3.08B | $59.53B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $111.00, up 0.17% with strong bullish technical indicators and unanimous analyst support. The stock shows robust fundamentals with 62.61% gross margins and accelerating revenue growth, projected to reach $319 million in 2026. Recent earnings beats and positive guidance highlight the company's momentum in hospitality technology solutions.
The outlook remains positive with 100% buy ratings and a $110 consensus target, though high valuation multiples (P/E 81.05) and overbought RSI levels suggest near-term consolidation risks. Long-term growth drivers include AI integration and subscription revenue expansion, but investors should monitor execution against elevated expectations.
BDX trades at $156.30, down 1.13% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations for Q1 2026, and the company maintains stable revenue growth, reaching $21.84B in 2025. Positive news highlights innovation in medical technology and dividend reliability, supporting a mixed but leaning positive analyst view.
Outlook is cautiously optimistic with a consensus price target of $172.33 offering ~10% upside. Risks include hospital spending caution and reimbursement uncertainty, but strong cash flow and product launches provide growth catalysts. The stock presents a balanced opportunity for dividend-focused investors amid moderate volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
